10X Genomics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? 10X Genomics Inc trades at $80.88 (market cap $10.07B), while Vanguard Information Technology Index Fund ETF trades at $128.1 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 16.9× 10X Genomics Inc's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| TXG | VGT | |
|---|---|---|
Market Cap | $10.07B | $170.20B |
Volume | 5,657,286 | 5,132,883 |
Sector | Health | — |
52-Week High | $97.74 | $129.79 |
52-Week Low | $11.48 | $83.59 |
Typical Hold Time | 91 Days | 129 Days |
Enterprise Value | $9.59B | — |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
VGT trades at $127.98, down 1.07% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong historical performance and appeal for long-term growth, with a focus on technology sector exposure. The ETF's low expense ratio and concentration in top tech names like Nvidia, Apple, and Microsoft are key attractions.
Outlook remains positive given tech sector momentum, but risks include high concentration in a few stocks and sensitivity to AI growth trends. Dividend yield is minimal, emphasizing capital appreciation over income. Investors should weigh sector volatility against long-term growth potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →